Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | ESRRG | P62508 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ESRRB | O95718 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16425977 | 0.91 | SLC6A4 (0.60) | SLC6A4DRD2ESRRGKDM4EESRRB | |
| SCHEMBL2603285 | 0.80 | HRH3 (0.56) | DRD2DRD3ESRRGESRRBESR1 | |
| SCHEMBL12609017 | 0.80 | HRH3 (0.56) | DRD2DRD3ESRRGESRRBESR1 | |
| SCHEMBL12609029 | 0.80 | HRH3 (0.56) | DRD2DRD3ESRRGESRRBESR1 | |
| SCHEMBL13698231 | 0.80 | SLC6A4 (0.61) | SLC6A4DRD2KDM4ECYP2D6SLC6A2 | |
| SCHEMBL23384128 | 0.78 | HTT (0.46) | DRD2DRD3CYP2D6CYP3A4 | |
| SCHEMBL16980529 | 0.78 | HPGD (0.46) | DRD2DRD3ESRRGESRRBESR1 | |
| SCHEMBL14136275 | 0.77 | DRD2 (0.71) | SLC6A4DRD2DRD3KDM4ECYP2D6 | |
| SCHEMBL13698254 | 0.77 | SLC6A4 (0.56) | SLC6A4DRD2DRD3CYP2D6SLC6A2 | |
| SCHEMBL14545786 | 0.77 | DRD3 (0.46) | SLC6A4DRD2DRD3ESRRGESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A4 221/4885DRD2 35/4885DRD3 32/4885 |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | SLC6A4 221/4885DRD2 35/4885DRD3 32/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A4 221/4885DRD2 35/4885DRD3 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.